Mendus (IMMU) Corporate presentation summary

Key investment highlights

• Vididencel immunotherapy targets unmet needs in AML and CML, aiming for durable, immune-mediated remissions.

• Phase 2 data in AML show 5-year overall survival of 63% versus less than 30% with standard of care.

• Broad clinical development strategy includes monotherapy and combination trials across AML and CML.

• Orphan Drug and Fast Track designations granted in the US and EU for AML.

• Robust pipeline with near-term milestones and global expansion, including pediatric and US-based trials.

Vididencel immunotherapy for myeloid malignancies

• Vididencel is an off-the-shelf, allogeneic dendritic cell therapy administered via intradermal injections.

• Demonstrates durable disease control and excellent safety profile in AML patients with measurable residual disease.

• Manufacturing is scalable, with established GMP alliances and regulatory validation.

• Potential for pediatric extension and eligibility for priority review voucher.

AML program

• Relapse after remission remains a major challenge; Vididencel is administered during first complete remission to reduce relapse.

• ADVANCE II Phase 2 trial shows majority of patients alive at 55 months, with mild side effects.

• CADENCE Phase 2b trial combines Vididencel with oral azacitidine, actively enrolling patients.

• DIVA Phase 1b trial will test Vididencel with venetoclax and azacitidine in transplant-ineligible patients, starting Q3 2026.

• US expansion includes pediatric trials in collaboration with MD Anderson and Children's Oncology Group.